AG2202T

AG2202T appears to be a formulation or variant of the drug AG2202, which is currently undergoing bioequivalence testing. The information available is limited. AG2202T is being developed by AHN-GOOK PHARMACEUTICAL Co., Ltd., a South Korean pharmaceutical company. It's currently in Phase 1 clinical trials, specifically in a bioequivalence study comparing it with AG2202R, another formulation of the same drug. The primary clinical trial for AG2202T is a Phase 1 bioequivalence study (NCT06549504) that aims to evaluate whether AG2202T and AG2202R release the same amount of the active drug into the bloodstream after being taken orally. This trial is scheduled to start on August 1, 2024, and is currently listed as "Not yet recruiting". AHN-GOOK PHARMACEUTICAL Co., Ltd. is a South Korean pharmaceutical company with several drugs in their pipeline. They have previously received approval for other drugs in South Korea, with their first approval dating back to March 2011.